Mark Purcell
Stock Analyst at Morgan Stanley
(0.79)
# 4,088
Out of 5,241 analysts
7
Total ratings
25%
Success rate
-7.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Maintains: Overweight | $143 → $170 | $148.08 | +14.80% | 2 | Mar 26, 2026 | |
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $42.69 | +35.86% | 2 | Sep 8, 2025 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $49.67 | -11.42% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $181.58 | -53.19% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $44.74 | +168.22% | 1 | Jan 23, 2024 |
Novartis AG
Mar 26, 2026
Maintains: Overweight
Price Target: $143 → $170
Current: $148.08
Upside: +14.80%
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $42.69
Upside: +35.86%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $49.67
Upside: -11.42%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $181.58
Upside: -53.19%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $44.74
Upside: +168.22%